ACC pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
Each arm uses its closest stored timepoint inside the window.
value
Source: Cited trial source for each arm. The timepoint in the table is the one this chart used.
No selected arm has this endpoint inside the time window.
Show as table
| Arm | Trial | Phase | Population | n | Comparator | Timepoint | Estimand | Assessor | Value |
|---|
Not shown
Every selected arm is drawn.
20 of 25 arms with a reported figure. Choose arms to narrow the chart.
months 10
Emiltatug Ledadotin (Emi-Le, XMT-1660) Phase 1 doses (not stated in source). median progression-free survival: 7.8 months, ASCO 2026; post hoc
Lenvatinib (off Label) 24 mg. median progression-free survival: 17.5 months, 8 progression events
Lenvatinib (off Label) 24 mg. median progression-free survival: 9.1 months, primary analysis
Axitinib (off Label) 5 mg. median progression-free survival: 10.8 months, primary analysis
Axitinib (off Label) none. median progression-free survival: 2.8 months, primary analysis
Axitinib (off Label) axitinib 5 mg twice daily + avelumab. median progression-free survival: 7.3 months, primary analysis
Axitinib (off Label) as above. median progression-free survival: 1.8 months, updated analysis; exploratory
Axitinib (off Label) as above. median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I
Rivoceranib 700 mg. median progression-free survival: 9 months, primary analysis
Amivantamab not stated in source. median progression-free survival: 4.6 months, results posted 05.08.2026
Bars in this group share the unit months. 17.5 months is the longest reported value here. A different unit is not redrawn onto this scale.
% 2
Axitinib (off Label) 5 mg. 6-month progression-free survival: 73%, 6 months
Axitinib (off Label) none. 6-month progression-free survival: 23%, 6 months
Bars in this group share the unit %. 73 % is the longest reported value here. A different unit is not redrawn onto this scale.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.